Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection
- PMID: 19569965
- DOI: 10.1086/600120
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection
Abstract
Background: To further increase the efficacy of malaria vaccine RTS,S/AS02A, we tested the RTS,S antigen formulated using the AS01B Adjuvant System (GlaxoSmithKline Biologicals).
Methods: In a double-blind, randomized trial, 102 healthy volunteers were evenly allocated to receive RTS,S/AS01B or RTS,S/AS02A vaccine at months 0, 1, and 2 of the study, followed by malaria challenge. Protected vaccine recipients were rechallenged 5 months later.
Results: RTS,S/AS01B and RTS,S/AS02A were well tolerated and were safe. The efficacy of RTS,S/AS01B and RTS,S/AS02A was 50% (95% confidence interval [CI], 32.9%-67.1%) and 32% (95% CI, 17.6%-47.6%), respectively. At the time of initial challenge, the RTS,S/AS01B group had greater circumsporozoite protein (CSP)-specific immune responses, including higher immunoglobulin (Ig) G titers, higher numbers of CSP-specific CD4(+) T cells expressing 2 activation markers (interleukin-2, interferon [IFN]-gamma, tumor necrosis factor-alpha, or CD40L), and more ex vivo IFN-gamma enzyme-linked immunospots (ELISPOTs) than did the RTS,S/AS02A group. Protected vaccine recipients had a higher CSP-specific IgG titer (geometric mean titer, 188 vs 73 mug/mL; P < .001), higher numbers of CSP-specific CD4(+) T cells per 10(6) CD4(+) T cells (median, 963 vs 308 CSP-specific CD4(+) T cells/10(6) CD4(+) T cells; P < .001), and higher numbers of ex vivo IFN-gamma ELISPOTs (mean, 212 vs 96 spots/million cells; P < .001). At rechallenge, 4 of 9 vaccine recipients in each group were still completely protected.
Conclusions: The RTS,S/AS01B malaria vaccine warrants comparative field trials with RTS,S/AS02A to determine the best formulation for the protection of children and infants. The association between complete protection and immune responses is a potential tool for further optimization of protection. Trial registration. ClinicalTrials.gov identifier NCT00075049.
Comment in
-
A malaria vaccine for control: more progress.J Infect Dis. 2009 Aug 1;200(3):317-20. doi: 10.1086/600121. J Infect Dis. 2009. PMID: 19569963 No abstract available.
-
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.J Infect Dis. 2009 Aug 1;200(3):329-36. doi: 10.1086/600119. J Infect Dis. 2009. PMID: 19569964 Clinical Trial.
-
Further analysis of correlates of protection from a phase 2a trial of the falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.J Infect Dis. 2010 Mar 15;201(6):970-1. doi: 10.1086/651025. J Infect Dis. 2010. PMID: 20170369 Clinical Trial. No abstract available.
Similar articles
-
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.Vaccine. 2006 Oct 30;24(42-43):6483-92. doi: 10.1016/j.vaccine.2006.06.033. Epub 2006 Jul 3. Vaccine. 2006. PMID: 16904798
-
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.J Infect Dis. 2009 Aug 1;200(3):329-36. doi: 10.1086/600119. J Infect Dis. 2009. PMID: 19569964 Clinical Trial.
-
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.Vaccine. 2005 Jul 14;23(32):4148-57. doi: 10.1016/j.vaccine.2005.03.019. Epub 2005 Apr 15. Vaccine. 2005. PMID: 15964483 Clinical Trial.
-
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.Vaccine. 2005 Mar 18;23(17-18):2243-50. doi: 10.1016/j.vaccine.2005.01.142. Vaccine. 2005. PMID: 15755604 Review.
-
RTS,S/AS02A for malaria.Expert Rev Vaccines. 2006 Oct;5(5):611-5. doi: 10.1586/14760584.5.5.611. Expert Rev Vaccines. 2006. PMID: 17181435 Review.
Cited by
-
The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.BMC Med. 2015 Jul 29;13:170. doi: 10.1186/s12916-015-0408-2. BMC Med. 2015. PMID: 26219380 Free PMC article. Clinical Trial.
-
Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice.Front Immunol. 2021 Mar 17;12:641421. doi: 10.3389/fimmu.2021.641421. eCollection 2021. Front Immunol. 2021. PMID: 33815393 Free PMC article.
-
Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Biomed Res Int. 2013;2013:282913. doi: 10.1155/2013/282913. Epub 2013 Apr 23. Biomed Res Int. 2013. PMID: 23710439 Free PMC article. Review.
-
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Malar J. 2009 Dec 30;8:312. doi: 10.1186/1475-2875-8-312. Malar J. 2009. PMID: 20042088 Free PMC article. Review.
-
Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.Proc Biol Sci. 2011 May 7;278(1710):1298-305. doi: 10.1098/rspb.2010.1697. Epub 2010 Oct 13. Proc Biol Sci. 2011. PMID: 20943696 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials